A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension

European Journal of Ophthalmology

Volumn 17, Issue 1, 2007, Pages 53-62

  Hommer, Anton ^a,c   Boone, W Benton ^b   Branch, James D ^b   Brigatti, Luca ^b   Christie, William C ^b   Clifford, William S ^b   Cooke, David L ^b   Corwin, Joel ^b   Davitt III, William F ^b   Burns, Jason ^b   De La Chapa, Jorge ^b   Digby, Donald ^b   DiSclafani, Mark ^b   Dorner, Martin ^b   Katzman, Barry ^b   Koch Schweitzer, Hartwig ^b   Krupin, Theodore ^b   Latina, Mark A ^b   Lederer, Charles ^b   Leopold, Martin R ^b   Lesk, Mark ^b   Mansouri, Arash ^b   Manusow, David ^b   Murphy, Paul ^b   Ochsner, Katherine ^b   Otto, Peter ^b   Pfeiffer, Norbert ^b   Piemontesi, Roberto ^b   Protzko, Eugene ^b   Rubin, Jay ^b   Rybiczka, Roman ^b   Scholzel, Sonja ^b   Sonty, Sriram ^b   Stewart, Robert H ^b   Tauber, Joseph ^b   Walters, Thomas R ^b   Batoosingh, Amy L ^b   Bossowska, Izabella ^b   Chou, Connie ^b   Ingram, Alison ^b   Novack, Gary D ^b   more..

^a Hera Hospital   (Austria)

^b NONE

^c NONE   (Austria)

Author keywords

Bimatoprost; Glaucoma; Intraocular pressure; Timolol

Indexed keywords

BIMATOPROST; TIMOLOL; AMIDE; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; DRUG DERIVATIVE; EYE DROPS; LIPID;

ABNORMAL SENSATION; ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE BURNING SENSATION; EYE PAIN; EYE STINGING SENSATION; EYELID EDEMA; FEMALE; FOREIGN BODY SENSATION; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL DISORDER; ADOLESCENT; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 34047271456     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210701700108     Document Type: Article

References (25)

1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40.
2. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002; 120: 1268-79.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13.
4. Kass MA. Efficacy of combining timolol with other antiglaucoma medications. Surv Ophthalmol 1983; 28 (Suppl): S274-9.
5. Gandolfi SA, Vecchi M. Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans. Invest Ophthalmol Vis Sci 1996; 37: 684-8.
6. Blackwell B. Treatment adherence. Br J Psychiatry 1976; 129: 513-31.
7. Baudouin C, Pisella P-J, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999; 106: 556-63.
8. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001; 131: 19-24.
9. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. Arch Ophthalmol 1978; 96: 2045-8.
10. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res 1978; 27: 135-42.
11. Cantor LB. An update on bimatoprost in glaucoma therapy. Exp Opin Pharmacother 2002; 3: 1753-62.
12. Brandt JD, Vandenburgh AM, Chen K, Whitcup SM. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001; 108: 1023-31.
13. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001; 45: S361-8.
14. Zimmerman TJ, Fechtner RD. Maximal medical therapy for glaucoma. Arch Ophthalmol 1997; 115: 1579-80.
15. Kaufman B, Novack GD. Compliance issues in manufacturing of drugs. Ocul Surf 2003; 1: 80-5.
16. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120: 1286-93.
17. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 2005; 14: 392-9.
18. Diestelhorst M, Larsson LI. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol 2004; 88: 199-203.
19. Diestelhorst M, Larsson LI. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 2006; 113: 70-6.
20. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure. A 30-day comparison with latanoprost. Surv Ophthalmol 2001; 45 (Suppl): S353-60.
21. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001; 18: 110-21.
22. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 63.
23. Parrish RK, Palmberg P, Sheu W-P, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol 2003; 135: 688-703.
24. Robin AL. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 921-2.
25. van Buskirk EM, Bacon DR, Fahrenbach WH. Ciliary vasoconstriction after topical adrenergic drugs. Am J Ophthalmol 1990; 109: 511-7.